Germany · Delayed Price · Currency is EUR Nicox Company Description
Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally.
The company develops solutions to maintain vision and improve ocular health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.
It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation.
In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular related associated with allergic conjunctivitis.
Nicox S.A. was founded in 1996 and is headquartered in Biot, France.
| Country | France |
| Founded | 1996 |
| Industry | Pharmaceutical Preparations |
| Employees | 5 |
| CEO | Gavin Spencer |
Contact Details
Address: Sundesk Sophia Antipolis Biot, 06410 France | |
| Phone | 33 4 97 24 53 00 |
| Website | nicox.com |
Stock Details
| Ticker Symbol | NXOA |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gavin Spencer | Chief Executive Officer |
| Sandrine Gestin | Chief Financial Officer |